Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > Pretty, pretty GUD...
View:
Post by gudisgood on May 12, 2022 4:46pm

Pretty, pretty GUD...

Always nice to see a strong report. Even better to find out about a new deal on the same day. In addition, the earnings call boosted my confidence in the company. And to end the day on a high note, GUD's trading at an even lower price than yesterday, so the company's likely to buy back more stock at cheaper prices. :)

I'll post more once I get a chance to re-listen and also read the report more carefully.

By the way, Exelon partly transferred over now:

Furthermore, Knight has received the regulatory notification that the
marketing authorization for Exelon® has transfered to Knight’s affiliate in May 2022 in Colombia and will transfer in June 2022 in Brazil
Comment by longrun86 on May 12, 2022 5:31pm
I am still digesting some of the more intricate details but my view is mixed on the Q1. Revenue: Great to see this coming in ahead of expectations. This was a big positive for me. Gross Margin: I am happy with this but think there is room to run by a few more percentage points on GM %. Operating Income: This is still below where it should be relative to the investment ...more  
Comment by EbbFlow88 on May 12, 2022 6:03pm
I somewhat agree on the investment fund side but I think Mugsy hit the nail on the head the other day. They have some time to continue to streamline GBT while adding smaller deals (today is a perfect example of a small accretive deal with little added G&A) and increase cash flow/buyback shares.  Then wait until the share price is higher and maybe use that shelf prospectus for a bigger ...more  
Comment by Chianchin on May 12, 2022 9:25pm
What else is new? Losing more money again? Nearly one billion in cash and GUD eight years later cannot make a single dollar profit. Shame on all of you "investors"  335 million dollars in Intangible assets? That is GBT. What is a goodwill and or intangible assets worth when it cannot earn 1 dollar? You got it ZERO
Comment by Chianchin on May 13, 2022 10:13am
.. regarding digesting the real defination is having a financial indigestion weezy stomach feelings 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities